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Clinical PerspectiveWhat Is New?This is the first individual participant data meta‐analysis examining the effect of vitamin D analogues on markers of vascular function that are surrogates for cardiovascular events.No consistent effect was found at trial level or on analysis of individual participant‐level data of supplementation on measures of endothelial function, arterial stiffness, or central blood pressure.No subgroup benefited consistently on analysis of individual participant data.What Are the Clinical Implications?This analysis did not find convincing evidence of benefit from Vitamin D supplementation on a range of markers of vascular function.

Introduction {#jah33189-sec-0008}
============

Low circulating levels of 25‐hydroxyvitamin D (25(OH)D) have been associated with a wide range of illness states and physiological derangements. Within the field of cardiometabolic medicine, low 25(OH)D levels have been associated with higher levels of blood pressure (BP), with diabetes mellitus, stroke, myocardial infarction, and heart failure[1](#jah33189-bib-0001){ref-type="ref"}, [2](#jah33189-bib-0002){ref-type="ref"} in observational studies. Vitamin D affects hundreds of gene targets and has effects on a wide variety of cell types and organ systems, including the heart and vascular system.[3](#jah33189-bib-0003){ref-type="ref"}, [4](#jah33189-bib-0004){ref-type="ref"} Several pathophysiological pathways have been postulated to explain the observed associations between low 25(OH)D levels and cardiovascular disease, including effects on arterial stiffness, endothelial function, cytokine secretion, vascular endothelial growth factor, and cellular calcium influx.[4](#jah33189-bib-0004){ref-type="ref"}

Despite a sound rationale for improved cardiovascular health with vitamin D supplementation, results from intervention trials have been less encouraging. A recent individual participant data (IPD) meta‐analysis reported that vitamin D supplementation had no significant effect on BP,[5](#jah33189-bib-0005){ref-type="ref"} even in those participants with low baseline 25(OH)D levels or with high baseline BP. Similarly, only marginal effects were observed on glycemic control in a meta‐analysis of vitamin D supplementation in participants with diabetes mellitus.[6](#jah33189-bib-0006){ref-type="ref"} Meta‐analyses of cardiovascular outcomes show no effect of vitamin D supplementation on myocardial infarction or stroke, but suggest a possible effect in reducing new diagnoses of heart failure.[7](#jah33189-bib-0007){ref-type="ref"} It is important to note that these meta‐analyses include mostly trials performed in participants at risk for falls or with osteoporosis and may therefore not be generalizable. Several large trials of vitamin D supplementation with adequate power to detect reductions in cardiovascular events are due to report over the next few years, but the first of these trials did not report any reduction in cardiovascular event rates in a population of older people in New Zealand.[8](#jah33189-bib-0008){ref-type="ref"}

These results call into question the causal link between vitamin D status and vascular health. Results from trials investigating the effect of vitamin D supplementation on aspects of vascular health other than BP have shown mixed results. Arterial stiffness and endothelial function measures are validated markers of cardiovascular disease risk and major adverse cardiac events, but the beneficial impact of vitamin D supplementation on these markers is unclear. We therefore performed a systematic review with meta‐analysis of trial‐level and individual participant‐level data to ascertain whether (1) vitamin D supplementation improves measures of arterial stiffness and endothelial function and (2) certain subgroups of individuals are more likely to benefit.

Methods {#jah33189-sec-0009}
=======

Data Sharing Statement {#jah33189-sec-0010}
----------------------

To preserve the rights of data owners, and as agreed with those who contributed data sets for this analysis, the data, analytical methods, and study materials will not be made available to other researchers for the purposes of reproducing the results or replicating the procedure.

Review Design and Search Strategy {#jah33189-sec-0011}
---------------------------------

We conducted a systematic review according to a prespecified protocol, which was registered on the PROSPERO database of systematic reviews. The protocol is accessible at: (<http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002816>). Ethics committee approval was not required because no new data were collected as part of this review. We included randomized controlled trials, which compared vitamin D or analogues with placebo, with a minimum exposure period of 4 weeks. The following databases were searched from inception to end of December 2016: Medline, EMBASE, CINAHL, ClinicalTrials.gov, and the Cochrane central register of controlled trials. Gray literature was sought using Google, and references of included studies were hand‐searched for further candidate trials. Only trials where a full published trial report was available were included; trials published in abstract form only were excluded.

Trial Selection {#jah33189-sec-0012}
---------------

Trials with changes in the following vascular markers were included: brachial artery flow‐mediated dilatation; reactive hyperemia index measures using finger plethysmography; pulse wave velocity (PWV) and pulse wave analysis; central aortic BP derived from peripheral artery tonometry; microvascular function measured using acetylcholine iontophoresis; and laser Doppler perfusion imaging. Studies with any baseline 25(OH)D level were eligible for inclusion. The following interventions were eligible for inclusion: vitamin D2 (ergocalciferol), vitamin D3 (cholecalciferol), calcitriol (1,25 hydroxyvitamin D3), 1‐alpha‐vitamin D, paricalcitol, and doxerocalciferol. Control groups receiving placebo were used and those receiving placebo plus cointervention were included, provided both arms of the study received the cointervention. A minimum of 4 weeks of therapy was necessary for inclusion to ensure sufficient time for vascular markers to change. Studies from both primary and secondary care or population settings were included; no restrictions were placed on sex or ethnicity. Studies recruiting participants less than 16 years old were not included, but in contrast to our previous review,[5](#jah33189-bib-0005){ref-type="ref"} we did include studies of participants on renal replacement therapy (hemodialysis or peritoneal dialysis) given their very high cardiovascular risk and the current interest in using vitamin D supplementation therapy in this group.

Data Extraction {#jah33189-sec-0013}
---------------

Data were extracted independently by 2 researchers (L.A.B. and M.D.W.) and differences resolved by consensus. Baseline trial population data were identified, including age, sex, ethnicity, diabetes mellitus, kidney function, history of cardiovascular events, history of hypertension, baseline BP, and baseline use of angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blockers, and statins. For each measure of vascular function, we recorded change in the outcome in each group between baseline and the last follow‐up visit. Study authors were contacted if data were incomplete or ambiguous in primary reports.

IPD Collection {#jah33189-sec-0014}
--------------

Lead authors for each included trial were contacted and invited to contribute individual‐level participant data. Data were anonymized and transferred using a standard template before cleaning and incorporation in the final data set. Individual‐level participant data were sought for age, sex, body mass index, baseline and follow‐up 25(OH)D level, baseline medication use including ACE inhibitors and angiotensin receptor blockers, baseline estimated glomerular filtration rate (eGFR), total cholesterol, serum calcium and parathyroid hormone (PTH), presence of diabetes mellitus and previous vascular events, baseline and follow up BP and cholesterol, and baseline and follow‐up measures of vascular function.

Risk of Bias Assessment {#jah33189-sec-0015}
-----------------------

Risk of bias was evaluated by 2 authors independently, with discrepancies resolved by consensus. We assessed each included study for risk for bias using the following fields from a risk of bias checklist[9](#jah33189-bib-0009){ref-type="ref"}: quality of random allocation concealment, intention‐to‐treat analysis, blinding of outcome assessors, treatment and control group comparability, clear definition of inclusion and exclusion criteria, participant blinding to allocation, and description of withdrawals and dropouts. Funnel plots were generated and inspected for evidence of publication bias, supplemented by Egger\'s test for funnel plot asymmetry.

Statistical Analysis {#jah33189-sec-0016}
--------------------

Meta‐analysis at the trial level was performed using RevMan 5.3 software (Cochrane Collaboration). For all analyses, random‐effects and fixed‐effects meta‐analyses using a weighted least‐squares approach were performed. For outcomes measured with the same technique and same units (most brachial‐artery flow‐mediated dilatation \[FMD\] measures, reactive hyperemia index, augmentation index \[AIx\], central BP, and subgroups of PWV), results were expressed as mean difference between groups. For comparisons where dissimilar units were combined, results were expressed as standardized mean difference (SMD). Heterogeneity was assessed using the I^2^ statistic. Trial‐level meta‐regression was undertaken for FMD, PWV, and augmentation index outcomes, regressing treatment effect on daily dose equivalent (for trials using vitamin D3) and trial duration in months. Metaregression was not used for other outcomes because there were too few to produce reliable results. Metaregression was undertaken using Comprehensive Meta Analysis tools software (version 3; Biostat, Englewood, NJ).

A 2‐stage analysis was used for IPD.[10](#jah33189-bib-0010){ref-type="ref"} For each trial, or subgroup within each trial, mean outcome values at follow‐up in each group were calculated and adjusted for baseline outcome values using ANCOVA (SPSS version 24; IBM, Armonk, NY). These values were then combined using RevMan software as described above. For those trials using more than 1 type or dose of vitamin D, the vitamin D arms were analyzed as a single arm. The following prespecified subgroup analyses were performed: diabetes mellitus versus no diabetes mellitus; baseline systolic BP of no greater than 140 mm Hg versus greater than 140 mm Hg; diastolic BP of no greater than 90 mm Hg versus greater than 90 mm Hg; baseline PTH level of above versus below median level for the IPD set; baseline adjusted serum calcium level and baseline total cholesterol above versus below median level for the individual participant data set; estimated glomerular filtration rate (eGFR) 60 mL/min per 1.73 m^2^ or above versus subgroups of eGFR below 60 mL/min per 1.73 m^2^; baseline 25(OH)D level of less than 25, 25 to 50, and greater than 50 nmol/L; and baseline ACE inhibitor versus no ACE inhibitor use. For analyses of ACE inhibitor use, participants taking angiotensin receptor blockers were excluded given their similar, but not identical, biological effects. Subgroups for analysis were selected on the basis of possible mechanisms by which vitamin D might act (eg, through effects on the renin‐angiotensin system or by suppressing PTH),[4](#jah33189-bib-0004){ref-type="ref"} to explore groups thought to be most likely to benefit (eg, high BP, low 25(OH)D levels), and to identify disease populations that might be targeted by future studies (diabetes mellitus, chronic kidney disease \[CKD\]). For CKD, subgroups of eGFR 45 to 59, 30 to 44, 15 to 29, and \<15 mL/min per 1.73 m^2^ were used where sufficient numbers of participants were available for the outcome; for outcomes with small numbers of participants, these subgroups were collapsed into a category eGFR \<60 mL/min per 1.73 m^2^. Participants on dialysis were included in the \<15 mL/min per 1.73 m^2^ subgroup.

Results {#jah33189-sec-0017}
=======

A total of 31 trials, involving 2751 participants, were eligible for inclusion in the review.[11](#jah33189-bib-0011){ref-type="ref"}, [12](#jah33189-bib-0012){ref-type="ref"}, [13](#jah33189-bib-0013){ref-type="ref"}, [14](#jah33189-bib-0014){ref-type="ref"}, [15](#jah33189-bib-0015){ref-type="ref"}, [16](#jah33189-bib-0016){ref-type="ref"}, [17](#jah33189-bib-0017){ref-type="ref"}, [18](#jah33189-bib-0018){ref-type="ref"}, [19](#jah33189-bib-0019){ref-type="ref"}, [20](#jah33189-bib-0020){ref-type="ref"}, [21](#jah33189-bib-0021){ref-type="ref"}, [22](#jah33189-bib-0022){ref-type="ref"}, [23](#jah33189-bib-0023){ref-type="ref"}, [24](#jah33189-bib-0024){ref-type="ref"}, [25](#jah33189-bib-0025){ref-type="ref"}, [26](#jah33189-bib-0026){ref-type="ref"}, [27](#jah33189-bib-0027){ref-type="ref"}, [28](#jah33189-bib-0028){ref-type="ref"}, [29](#jah33189-bib-0029){ref-type="ref"}, [30](#jah33189-bib-0030){ref-type="ref"}, [31](#jah33189-bib-0031){ref-type="ref"}, [32](#jah33189-bib-0032){ref-type="ref"}, [33](#jah33189-bib-0033){ref-type="ref"}, [34](#jah33189-bib-0034){ref-type="ref"}, [35](#jah33189-bib-0035){ref-type="ref"}, [36](#jah33189-bib-0036){ref-type="ref"}, [37](#jah33189-bib-0037){ref-type="ref"}, [38](#jah33189-bib-0038){ref-type="ref"}, [39](#jah33189-bib-0039){ref-type="ref"}, [40](#jah33189-bib-0040){ref-type="ref"}, [41](#jah33189-bib-0041){ref-type="ref"} Of these, 29 trials (2641 participants) had data suitable for inclusion in the trial‐level meta‐analyses; IPD were obtained from 24 trials (2051 participants). The PRISMA flowchart is shown in [Figure](#jah33189-fig-0001){ref-type="fig"}. One study that did not include data in the published article suitable for trial‐level meta‐analysis[36](#jah33189-bib-0036){ref-type="ref"} provided IPD data and was included in the IPD analyses. Study size ranged from 24 to 305 participants; vitamin D3 was the most common intervention, being used in 23 of 31 (74%) of trials. The daily dose equivalent given in trials of vitamin D3 ranged from 900 to 5000 IU, and the duration of administration ranged from 4 weeks to 12 months. Paricalcitol was the only activated vitamin D analogue used in studies included in this review. Table [1](#jah33189-tbl-0001){ref-type="table"} shows which vascular outcomes were measured in each included trial, and baseline trial characteristics are shown in Table [2](#jah33189-tbl-0002){ref-type="table"}.

![PRISMA diagram showing trial selection.](JAH3-7-e008273-g001){#jah33189-fig-0001}

###### 

Measurements From Included Studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Title and Year                                              Preparation Tested   FMD   PWV   AIx   RHI   Central BP   Microvascular Function   Included in IPD Analysis?
  ----------------------------------------------------------- -------------------- ----- ----- ----- ----- ------------ ------------------------ ---------------------------
  Alborzi 2008[11](#jah33189-bib-0011){ref-type="ref"}        Paricalcitol         X                                                             No

  Sugden 2008[12](#jah33189-bib-0012){ref-type="ref"}         Vitamin D2           X                                                             Yes

  Witham 2010[13](#jah33189-bib-0013){ref-type="ref"}         Vitamin D3           X                                                             Yes

  Harris 2011[14](#jah33189-bib-0014){ref-type="ref"}         Vitamin D3           X                                                             Yes

  Gepner 2012[15](#jah33189-bib-0015){ref-type="ref"}         Vitamin D3           X     X     X           X                                     Yes

  Larsen 2012[16](#jah33189-bib-0016){ref-type="ref"}         Vitamin D3                 X     X           X                                     Yes

  Marckmann 2012[17](#jah33189-bib-0017){ref-type="ref"}      Vitamin D3                 X     X           X                                     Yes

  Sokol 2012[18](#jah33189-bib-0018){ref-type="ref"}          Vitamin D2                             X                                           Yes

  Stricker 2012[19](#jah33189-bib-0019){ref-type="ref"}       Vitamin D3                       X           X            X                        Yes

  Witham 2012[20](#jah33189-bib-0020){ref-type="ref"}         Vitamin D2           X                                                             Yes

  Breslavsky 2013[21](#jah33189-bib-0021){ref-type="ref"}     Vitamin D3                       X                                                 Yes

  Hewitt 2013[22](#jah33189-bib-0022){ref-type="ref"}         Vitamin D3                 X                                                       No

  Witham 2013[23](#jah33189-bib-0023){ref-type="ref"}         Vitamin D3           X     X                                                       Yes

  Witham 2013[24](#jah33189-bib-0024){ref-type="ref"}         Vitamin D3                             X                                           Yes

  Witham 2013[25](#jah33189-bib-0025){ref-type="ref"}         Vitamin D3           X     X     X           X            X                        Yes

  Yiu 2013[26](#jah33189-bib-0026){ref-type="ref"}            Vitamin D3           X     X                                                       No

  Dreyer 2014[27](#jah33189-bib-0027){ref-type="ref"}         Vitamin D2                 X                              X                        Yes

  Martins 2014[28](#jah33189-bib-0028){ref-type="ref"}        Vitamin D3                       X                                                 No

  Mose 2014[29](#jah33189-bib-0029){ref-type="ref"}           Vitamin D3                 X     X           X                                     Yes

  Ryu 2014[30](#jah33189-bib-0030){ref-type="ref"}            Vitamin D3                 X     X                                                 No

  Zoccali 2014[31](#jah33189-bib-0031){ref-type="ref"}        Paricalcitol         X                                                             Yes

  Garg 2015[32](#jah33189-bib-0032){ref-type="ref"}           Vitamin D3                 X     X                                                 Yes

  Pilz 2015[33](#jah33189-bib-0033){ref-type="ref"}           Vitamin D3                 X                                                       Yes

  Thethi 2015[34](#jah33189-bib-0034){ref-type="ref"}         Paricalcitol         X                                                             No

  Witham 2015[35](#jah33189-bib-0035){ref-type="ref"}         Vitamin D3           X     X     X                                                 Yes

  Barchetta 2016[36](#jah33189-bib-0036){ref-type="ref"}      Vitamin D3           X                                                             Yes

  Borgi 2017[37](#jah33189-bib-0037){ref-type="ref"}          Vitamin D2           X                                                             No

  Bressendorff 2016[38](#jah33189-bib-0038){ref-type="ref"}   Vitamin D3                 X     X           X                                     Yes

  Dalan 2016[39](#jah33189-bib-0039){ref-type="ref"}          Vitamin D3                       X     X                                           Yes

  Forouhi 2016[40](#jah33189-bib-0040){ref-type="ref"}        Vitamin D2\                X                                                       Yes
                                                              Vitamin D3                                                                         

  Hin 2017[41](#jah33189-bib-0041){ref-type="ref"}            Vitamin D3                 X     X                                                 Yes
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AIx indicates augmentation index; BP, blood pressure; FMD, flow‐mediated dilatation of the brachial artery; IPD, individual participant data; PWV, pulse wave velocity; RHI, reactive hyperemia index.

###### 

Details of Included Studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                                                   N     Latitude   Study Population                                                            Mean Age, y   \% Male   25(OH)D Range for Inclusion (nmol/L)   Mean Baseline 25(OH)D (nmol/L)   Mean Baseline SBP (mm Hg)   Control                         Intervention                                                                       Duration
  ------------------------------------------------------------------------------------------------------- ----- ---------- --------------------------------------------------------------------------- ------------- --------- -------------------------------------- -------------------------------- --------------------------- ------------------------------- ---------------------------------------------------------------------------------- ----------
  Alborzi,[11](#jah33189-bib-0011){ref-type="ref"} USA, 2008                                              24    40°N       CKD and on ACE‐I or ARB                                                     70            83        No restriction                         34                               125.4 (24 hours BP)         Placebo                         Paricalcitol 1 μg daily\                                                           1 mo
                                                                                                                                                                                                                                                                                                                                                                   Paricalcitol 2 μg daily                                                            

  Sugden,[12](#jah33189-bib-0012){ref-type="ref"} Scotland, 2008                                          34    56°N       Type 2 diabetes mellitus                                                    64            53        \<50                                   38                               141                         Placebo                         Ergocalciferol\                                                                    8 wks
                                                                                                                                                                                                                                                                                                                                                                   100 000 IU single dose                                                             

  Witham,[13](#jah33189-bib-0013){ref-type="ref"} Scotland, 2010                                          61    56°N       Type 2 diabetes mellitus                                                    65            67        \<100                                  45                               146                         Placebo                         100 000 IU Cholecalciferol\                                                        16 wks
                                                                                                                                                                                                                                                                                                                                                                   200 000 IU cholecalciferol single dose                                             

  Harris,[14](#jah33189-bib-0014){ref-type="ref"} USA, 2011                                               45    33°N       Black adults with no overt cardiovascular, pulmonary or metabolic disease   30            47        No restriction                         36                               124                         Placebo                         Cholecalciferol 60 000 IU/4 weekly                                                 16 wks

  Gepner,[15](#jah33189-bib-0015){ref-type="ref"} USA, 2012                                               114   43°N       Healthy community dwelling postmenopausal females                           64            0         \>25 and \<150                         78                               119.4                       Placebo                         Cholecalciferol 2500 IU/day                                                        4 mo

  Larsen,[16](#jah33189-bib-0016){ref-type="ref"} Denmark, 2012                                           130   56°N       Hypertension                                                                61            31        No restriction                         58                               143                         Placebo                         Cholecalciferol 3000 IU/day                                                        20 wks

  Marckmann,[17](#jah33189-bib-0017){ref-type="ref"} Denmark, 2012                                        52    55°N       CKD                                                                         67            75        \<50                                   33                               138                         Placebo                         Cholecalciferol 40 000 IU weekly                                                   8 wks

  Sokol,[18](#jah33189-bib-0018){ref-type="ref"} USA, 2012                                                90    41°N       Angiographically confirmed coronary artery disease                          56            73        \<50                                   ?                                133                         Placebo                         Ergocalciferol 50 000 IU weekly                                                    12 wks

  Stricker,[19](#jah33189-bib-0019){ref-type="ref"} Switzerland, 2012                                     62    46°N       Chronic peripheral vascular disease and vitamin D deficiency                74            61        \<75                                   42                               137                         Placebo                         Cholecalciferol (vitamin D3) 100 000 IU single dose                                1 mo

  Witham,[20](#jah33189-bib-0020){ref-type="ref"} Scotland, 2012                                          58    56°N       Older adults with previous stroke                                           67            72        \<75                                   38                               128                         Placebo                         100 000 IU Ergocalciferol single dose                                              16 wks

  Breslavsky,[21](#jah33189-bib-0021){ref-type="ref"} Israel, 2013                                        47    32°N       Type 2 diabetes mellitus with cardiovascular risk factors                   66            47        No restriction                         30                               153                         Placebo                         Cholecalciferol 1000 IU daily                                                      12 mo

  Hewitt,[22](#jah33189-bib-0022){ref-type="ref"} Australia, 2013                                         60    34°S       Adults on hemodialysis                                                      ?             48        \<60                                   43                               152                         Placebo                         Cholecalciferol 50 000 IU weekly for 8 wks, then monthly for 4 mo                  6 mo

  Witham,[23](#jah33189-bib-0023){ref-type="ref"} Scotland, 2013                                          159   56°N       Isolated systolic hypertension in over 70 year olds                         77            52        \<75                                   45                               163                         Placebo                         Cholecalciferol 100 000 IU 3 monthly                                               12 mo

  Witham,[24](#jah33189-bib-0024){ref-type="ref"} Scotland, 2013                                          75    56°N       Recent myocardial infarction                                                66            69        No restriction                         47                               127.5                       Placebo                         Cholecalciferol 100 000 IU/2 monthly                                               6 mo

  Witham,[25](#jah33189-bib-0025){ref-type="ref"} Scotland, 2013                                          50    56°N       South‐East Asian women living in UK for 10 y                                41            0         \<75                                   27                               120                         Placebo                         Cholecalciferol 100 000 IU single dose                                             8 wks

  Yiu,[26](#jah33189-bib-0026){ref-type="ref"} Hong Kong, 2013                                            100   22°N       Type 2 diabetes mellitus with suboptimal vitamin D status                   65            50        \<75                                   54                               146                         Placebo                         Cholecalciferol 5000 IU daily                                                      12 wks

  Dreyer,[27](#jah33189-bib-0027){ref-type="ref"} England, 2014                                           38    51°N       CKD stage 3 to 4                                                            47            74        \<40                                   25                               116                         Placebo                         Ergocalciferol 50 000 IU weekly for 1 mo, then monthly for 5 mo                    6 mo

  Martins,[28](#jah33189-bib-0028){ref-type="ref"} USA, 2014                                              130   34°N       Overweight blacks with hypertension                                         18 to 70      61        25 to 63                               43                               127                         Placebo                         Cholecalciferol 100 000 IU monthly                                                 3 mo

  Mose,[29](#jah33189-bib-0029){ref-type="ref"} Denmark, 2014                                             50    56°N       Hemodialysis or peritoneal dialysis                                         68            64        No restriction                         39                               136                         Placebo                         Cholecalciferol 3000 IU daily                                                      6 mo

  Ryu,[30](#jah33189-bib-0030){ref-type="ref"} Korea, 2014                                                62    38°N       Type 2 diabetes mellitus aged 30 to 69 y                                    56            ?         \<50                                   29                               130                         Placebo+200 mg calcium daily    Cholecalciferol 2000 IU daily+200 mg calcium daily                                 24 wks

  Zoccali,[31](#jah33189-bib-0031){ref-type="ref"} Italy, 2014                                            88    39°N       CKD stage 3 to 4 and PTH \>65 pg/mL                                         63            65        No restriction                         36                               126                         Placebo                         Paricalcitol 2 μg daily                                                            12 wks

  Garg,[32](#jah33189-bib-0032){ref-type="ref"} India, 2015                                               32    29°N       Women aged 18 to 35 y with polycystic ovary syndrome                        22            0         No restriction                         36                               Not known                   Placebo+1.5 g metformin daily   120 000 IU Cholecalciferol monthly+1.5 g metformin daily                           6 mo

  Pilz,[33](#jah33189-bib-0033){ref-type="ref"} Austria, 2015                                             188   47°N       Hypertension                                                                60            53        \<75                                   53                               143                         Placebo                         Cholecalciferol 2800 IU daily                                                      8 wks

  Thethi,[34](#jah33189-bib-0034){ref-type="ref"} USA, 2015                                               55    30°N       CKD 3 to 4 and type 2 diabetes mellitus                                     63            67        No restriction                         NA                               136                         Placebo                         Paricalcitol 1 μg daily                                                            12 wks

  Witham,[35](#jah33189-bib-0035){ref-type="ref"} Scotland, 2015                                          50    56°N       Chronic fatigue syndrome                                                    49            24        \<75                                   46                               128.5                       Placebo                         Cholecalciferol 100 000 IU/2 monthly                                               6 mo

  Barchetta.[36](#jah33189-bib-0036){ref-type="ref"} Italy. 2016                                          55    42°N       Type 2 diabetes mellitus with nonalcoholic fatty liver disease              58            70        No restriction                         NA                               131                         Placebo                         Cholecalciferol 2000 IU daily                                                      24 wks

  Borgi,[37](#jah33189-bib-0037){ref-type="ref"} USA, 2017                                                93    42°N       Overweight or obese nonhypertensives with vitamin D deficiency              37            ?         \<50                                   NA                               118                         Placebo                         Ergocalciferol 50 000 IU weekly                                                    8 wks

  Bressendorff,[38](#jah33189-bib-0038){ref-type="ref"} Denmark, 2016                                     40    56°N       Normotensive adults with vitamin D deficiency                               43            58        \<50                                   32                               118                         Placebo                         Cholecalciferol 3000 IU daily                                                      16 wks

  Dalan,[39](#jah33189-bib-0039){ref-type="ref"} Singapore, 2016                                          64    1°N        Multiethnic group with type 2 diabetes mellitus                             54            52        No restriction                         45                               139                         Placebo                         Cholecalciferol 2000 to 4000 IU daily depending on baseline 25(OH)D and response   16 wks

  Forouhi,[40](#jah33189-bib-0040){ref-type="ref"} England, 2016[a](#jah33189-note-0003){ref-type="fn"}   160   52°N       Adults with elevated risk of type 2 diabetes mellitus                       53            57        No restriction                         52                               128                         Placebo                         Ergocalciferol 100 000 IU monthly\                                                 4 mo
                                                                                                                                                                                                                                                                                                                                                                   Cholecalciferol 100 000 IU monthly                                                 

  Hin,[41](#jah33189-bib-0041){ref-type="ref"} England, 2017                                              305   52°N       Aged ≥65 y                                                                  72            51        No restriction                         50                               131                         Placebo                         Cholecalciferol 2000 IU daily\                                                     12 mo
                                                                                                                                                                                                                                                                                                                                                                   Cholecalciferol 4000 IU daily                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

25(OH)D indicates 25‐hydroxyvitamin D; ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CKD, chronic kidney disease; NA, not available; SBP, systolic blood pressure.

Data from 1 of 2 centers included as vascular function measured only at 1 center.

Risk of Bias Assessment {#jah33189-sec-0018}
-----------------------

Overall risk of bias was low. Most trials (27 of 31) reported clear evidence of effective allocation concealment, and most trials reported clear evidence for masking of participants (30 of 31), healthcare professionals (30 of 31), and outcomes assessors (29 of 31). Groups were comparable at baseline in 27 of 31 trials, dropouts were clearly described in 27 of 31 trials, but analysis was clearly by intention to treat in only 16 of 31 trials. A full description of the quality assessment for each trial is shown in Table [3](#jah33189-tbl-0003){ref-type="table"}. Funnel plots showed no asymmetry for any of the vascular outcomes; Egger\'s test was calculated only for those outcomes with at least 10 trials to ensure reliability; this was nonsignificant for FMD (*P*=0.18), AIx (*P*=0.32), and PVW (*P*=0.70).

###### 

Risk of Bias Assessment of Included Studies

  Title and Year                                              Quality of Allocation Concealment   Analysis on Intention to Treat   No. and Description of Dropouts   Blinding---Participants   Blinding---Health Care Providers   Blinding---Outcome Assessors   Comparable Treatment and Placebo Groups
  ----------------------------------------------------------- ----------------------------------- -------------------------------- --------------------------------- ------------------------- ---------------------------------- ------------------------------ -----------------------------------------
  Alborzi 2008[11](#jah33189-bib-0011){ref-type="ref"}        \+                                  \+                               \+                                \+                        \+                                 \+                             −
  Sugden 2008[12](#jah33189-bib-0012){ref-type="ref"}         \+                                  −                                \+                                \+                        \+                                 \+                             \+
  Witham 2010[13](#jah33189-bib-0013){ref-type="ref"}         \+                                  U                                \+                                \+                        \+                                 \+                             \+
  Harris 2011[14](#jah33189-bib-0014){ref-type="ref"}         \+                                  U                                \+                                \+                        \+                                 \+                             \+
  Gepner 2012[15](#jah33189-bib-0015){ref-type="ref"}         \+                                  \+                               \+                                \+                        \+                                 \+                             \+
  Larsen 2012[16](#jah33189-bib-0016){ref-type="ref"}         \+                                  −                                \+                                \+                        \+                                 \+                             \+
  Marckmann 2012[17](#jah33189-bib-0017){ref-type="ref"}      \+                                  −                                \+                                \+                        \+                                 \+                             \+
  Sokol 2012[18](#jah33189-bib-0018){ref-type="ref"}          \+                                  \+                               U                                 \+                        \+                                 \+                             \+
  Stricker 2012[19](#jah33189-bib-0019){ref-type="ref"}       \+                                  \+                               \+                                \+                        \+                                 \+                             −
  Witham 2012[20](#jah33189-bib-0020){ref-type="ref"}         \+                                  U                                \+                                \+                        \+                                 \+                             \+
  Breslavsky 2013[21](#jah33189-bib-0021){ref-type="ref"}     \+                                  −                                \+                                U                         U                                  U                              \+
  Hewitt 2013[22](#jah33189-bib-0022){ref-type="ref"}         \+                                  U                                \+                                \+                        \+                                 \+                             \+
  Witham 2013[23](#jah33189-bib-0023){ref-type="ref"}         \+                                  −                                \+                                \+                        \+                                 \+                             \+
  Witham 2013[24](#jah33189-bib-0024){ref-type="ref"}         \+                                  \+                               \+                                \+                        \+                                 \+                             \+
  Witham 2013[25](#jah33189-bib-0025){ref-type="ref"}         \+                                  \+                               \+                                \+                        \+                                 \+                             \+
  Yiu 2013[26](#jah33189-bib-0026){ref-type="ref"}            \+                                  \+                               \+                                \+                        \+                                 \+                             \+
  Dreyer 2014[27](#jah33189-bib-0027){ref-type="ref"}         \+                                  \+                               \+                                \+                        \+                                 \+                             \+
  Martins 2014[28](#jah33189-bib-0028){ref-type="ref"}        U                                   \+                               \+                                \+                        \+                                 \+                             \+
  Mose 2014[29](#jah33189-bib-0029){ref-type="ref"}           \+                                  U                                \+                                \+                        \+                                 \+                             \+
  Ryu 2014[30](#jah33189-bib-0030){ref-type="ref"}            U                                   −                                \+                                \+                        \+                                 \+                             \+
  Zoccali 2014[31](#jah33189-bib-0031){ref-type="ref"}        \+                                  \+                               \+                                \+                        \+                                 \+                             \+
  Garg 2015[32](#jah33189-bib-0032){ref-type="ref"}           U                                   −                                \+                                \+                        \+                                 \+                             \+
  Pilz 2015[33](#jah33189-bib-0033){ref-type="ref"}           \+                                  \+                               \+                                \+                        \+                                 \+                             \+
  Thethi 2015[34](#jah33189-bib-0034){ref-type="ref"}         U                                   U                                U                                 \+                        \+                                 U                              \+
  Witham 2015[35](#jah33189-bib-0035){ref-type="ref"}         \+                                  \+                               \+                                \+                        \+                                 \+                             \+
  Barchetta 2016[36](#jah33189-bib-0036){ref-type="ref"}      \+                                  −                                \+                                \+                        \+                                 \+                             \+
  Borgi 2017[37](#jah33189-bib-0037){ref-type="ref"}          \+                                  \+                               −                                 \+                        \+                                 \+                             \+
  Bressendorff 2016[38](#jah33189-bib-0038){ref-type="ref"}   \+                                  U                                \+                                \+                        \+                                 \+                             \+
  Dalan 2016[39](#jah33189-bib-0039){ref-type="ref"}          \+                                  \+                               U                                 \+                        \+                                 \+                             −
  Forouhi 2016[40](#jah33189-bib-0040){ref-type="ref"}        \+                                  \+                               \+                                \+                        \+                                 \+                             \+
  Hin 2017[41](#jah33189-bib-0041){ref-type="ref"}            \+                                  \+                               \+                                \+                        \+                                 \+                             \+

− indicates high risk of bias; +, low risk of bias; U, unclear risk of bias.

Trial‐Level Data {#jah33189-sec-0019}
----------------

Meta‐analysis of trial‐level data showed no significant treatment effect of vitamin D analogues on FMD (mean difference, 0.5%; 95% confidence interval \[CI\], −0.1 to 1.1; *P*=0.12), PVW (SMD, 0.02; 95% CI, −0.13 to 0.17; *P*=0.81), AIx (mean difference, 0.0%; 95% CI, −1.3 to 1.3; *P*=0.98), reactive hyperemia index (mean difference, 0.02 units; 95% CI, −0.11 to 0.14; *P*=0.79), or central BP. Microvascular function measured by laser Doppler iontophoresis (SMD, 0.43; 95% CI, 0.09--0.76; *P*=0.01) showed a modest improvement with vitamin D supplementation. Results are shown in Table [4](#jah33189-tbl-0004){ref-type="table"}. Fixed‐effects analyses showed similar point estimates, but narrower CIs, leading to a significant treatment effect for all vitamin D analogues on FMD (mean difference, 0.5%; 95% CI, 0.1--0.9; *P*=0.02). On subgroup analysis by treatment type, only paricalcitol showed a significant treatment benefit on FMD (mean difference, 1.7%; 95% CI, 0.6--2.8; *P*=0.002); analysis for interaction showed no significant difference between the paricalcitol treatment effect and that for vitamin D3 (*P*=0.62) or vitamin D2 (*P*=0.17). No significant difference was evident in the effects of daily dosing versus intermittent dosing either for FMD (mean difference, 0.85% \[95% CI, 0.01--1.69\] for daily dosing versus 0.26% \[95% CI, −0.58 to 1.11\] for intermittent dosing; *P*=0.06) or for PWV (SMD, 0.10 \[95% CI, −0.04 to 0.23\] for daily dosing versus −0.04 \[95% CI, −0.34 to 0.26\] for intermittent dosing; *P*=0.40). Metaregression results for daily dose equivalent and for trial duration are shown in Table [5](#jah33189-tbl-0005){ref-type="table"}. No association between these factors and treatment effect for PWV or AIx was found, but higher dose and shorter trial length were associated with a slightly greater treatment effect for FMD.

###### 

Trial‐Level Analysis of Effect Size: Vitamin D Supplementation and Markers of Vascular Function

  Outcome                                                                  Intervention                               No. of Studies   n                       Random‐Effects         Fixed‐Effects           I^2^                           
  ------------------------------------------------------------------------ ------------------------------------------ ---------------- ----------------------- ---------------------- ----------------------- ----------------------- ------ -----
  FMD (%)                                                                  All                                        12               785                     0.49 (−0.13 to 1.11)   0.12                    0.48 (0.06--0.90)       0.02   46%
  D3                                                                       7                                          495              0.17 (−0.49 to 0.84)    0.61                   0.19 (−0.30 to 0.67)    0.45                    38%    
  D2                                                                       3                                          163              0.79 (−1.04 to 2.62)    0.40                   0.91 (−0.39 to 2.21)    0.17                    45%    
  Paricalcitol                                                             2                                          103              1.72 (0.63--2.82)       0.002                  1.72 (0.63--2.82)       0.002                   0%     
  AIx (%)                                                                  All                                        14               1030                    0.0 (−1.3 to 1.3)      0.98                    0.0 (−1.1 to 1.1)       0.98   25%
  D3                                                                       14                                         1030             0.0 (−1.3 to 1.3)       0.98                   0.0 (−1.1 to 1.1)       0.98                    25%    
  D2                                                                       0                                          ···              ···                     ···                    ···                     ···                     ···    
  Paricalcitol                                                             0                                          ···              ···                     ···                    ···                     ···                     ···    
  RHI, units                                                               All                                        3                217                     0.02 (−0.11 to 0.14)   0.79                    0.02 (−0.11 to 0.14)    0.79   0%
  D3                                                                       2                                          130              0.02 (−0.18 to 0.21)    0.86                   0.04 (−0.10 to 0.18)    0.61                    37%    
  D2                                                                       1                                          87               −0.05 (−0.30 to 0.20)   0.70                   −0.05 (−0.30 to 0.20)   0.70                    ···    
  Paricalcitol                                                             0                                          ···              ···                     ···                                                                    ···    
  PWV (all; SMD)                                                           All                                        16               1333                    0.04 (−0.11 to 0.20)   0.60                    0.04 (−0.07 to 0.15)    0.50   44%
  D3                                                                       15                                         1304             0.05 (−0.11 to 0.21)    0.52                   0.04 (−0.07 to 0.15)    0.45                    47%    
  D2                                                                       2[a](#jah33189-note-0006){ref-type="fn"}   138              −0.24 (−0.57 to 0.10)   0.17                   −0.24 (−0.57 to 0.10)   0.17                    0%     
  Paricalcitol                                                             0                                          ···              ···                     ···                    ···                     ···                     ···    
  PWV (carotid‐femoral only; m/s)[a](#jah33189-note-0006){ref-type="fn"}   All                                        10               674                     0.04 (−0.32 to 0.41)   0.81                    −0.01 (−0.20 to 0.21)   0.94   58%
  D3                                                                       10                                         674              0.00 (−0.32 to 0.41)    0.81                   −0.01 (−0.20 to 0.21)   0.94                    58%    
  D2                                                                       1                                          107              −0.53 (−1.34 to 0.28)   0.20                   −0.53 (−1.34 to 0.28)   0.20                    ···    
  Paricalcitol                                                             0                                          ···              ···                     ···                    ···                     ···                     ···    
  PWV (others; SMD)                                                        All                                        6                659                     0.11 (−0.06 to 0.28)   0.22                    0.11 (−0.04 to 0.27)    0.15   8%
  D3                                                                       5                                          630              0.12 (−0.06 to 0.30)    0.19                   0.13 (−0.03 to 0.29)    0.11                    14%    
  D2                                                                       1                                          29               −0.20 (−0.93 to 0.53)   0.59                   −0.20 (−0.93 to 0.53)   0.59                    ···    
  Paricalcitol                                                             0                                          ···              ···                     ···                    ···                     ···                     ···    
  Microvascular function (SMD)                                             All                                        3                140                     0.43 (0.09--0.76)      0.01                    0.43 (0.09--0.76)       0.01   0%
  D3                                                                       2                                          111              0.37 (−0.01 to 0.75)    0.05                   0.37 (−0.01 to 0.75)    0.05                    0%     
  D2                                                                       1                                          29               0.65 (−0.10 to 1.41)    0.09                   0.65 (−0.10 to 1.41)    0.09                    ···    
  Paricalcitol                                                             0                                          ···              ···                     ···                    ···                     ···                     ···    
  Central SBP, mm Hg                                                       All                                        5                324                     −1.5 (−5.6 to 2.6)     0.46                    −1.2 (−3.8 to 1.4)      0.36   47%
  D3                                                                       5                                          324              −1.5 (−5.6 to 2.6)      0.46                   −1.2 (−3.8 to 1.4)      0.36                    47%    
  D2                                                                       0                                          ···              ···                     ···                    ···                     ···                     ···    
  Paricalcitol                                                             0                                          ···              ···                     ···                    ···                     ···                     ···    
  Central DBP, mm Hg                                                       All                                        5                324                     −0.8 (−2.2 to 0.6)     0.28                    −0.8 (−2.2 to 0.6)      0.28   0%
  D3                                                                       5                                          324              −0.8 (−2.2 to 0.6)      0.28                   −0.8 (−2.2 to 0.6)      0.28                    0%     
  D2                                                                       0                                          ···              ···                     ···                    ···                     ···                     ···    
  Paricalcitol                                                             0                                          ···              ···                     ···                    ···                     ···                     ···    

AIx indicates augmentation index; CI, confidence interval; D2, vitamin D2 (ergocalciferol); D3, vitamin D3 (cholecalciferol); DBP, diastolic blood pressure; FMD, flow‐mediated dilatation of the brachial artery; PWV, pulse wave velocity; RHI, reactive hyperemia index; SBP, systolic blood pressure; SMD, standardized mean difference.

Data from Forouhi et al[40](#jah33189-bib-0040){ref-type="ref"} contain comparisons of D3 vs placebo and D2 vs placebo. Only D3 analysis was included in "All" category for PWV analyses.

###### 

Results of Trial‐Level Metaregression

  Outcome                 Moderator Variable   No. of Trials          Random‐Effects           Fixed‐Effects          Regression Coefficient Units                          
  ----------------------- -------------------- ---------------------- ------------------------ ---------------------- ------------------------------ ---------------------- -----------
  FMD (%)                 Trial duration       11                     −0.06 (−0.11 to −0.01)   0.03                   −0.06 (−0.10 to −0.01)         0.009                  \% per mo
  Daily dose equivalent   6                    0.14 (0.01--0.27)      0.03                     0.14 (0.01--0.27)      0.03                           \% per 1000 units D3   
  PWV (SMD)               Trial duration       16                     0.01 (−0.04 to 0.06)     0.77                   0.02 (−0.01 to 0.05)           0.18                   SD per mo
  Daily dose equivalent   15                   0.07 (−0.08 to 0.23)   0.35                     0.06 (−0.05 to 0.17)   0.29                           SD per 1000 units D3   
  AIx (%)                 Trial duration       14                     −0.01 (−0.05 to 0.04)    0.73                   −0.00 (−0.04 to 0.03)          0.84                   \% per mo
  Daily dose equivalent   14                   0.10 (−0.06 to 0.25)   0.22                     0.09 (−0.04 to 0.23)   0.18                           \% per 1000 units D3   

AIx indicates augmentation index; CI, confidence interval; FMD, flow‐mediated dilatation of the brachial artery; PWV, pulse wave velocity; SMD, standardized mean difference.

Individual Participant Data {#jah33189-sec-0020}
---------------------------

Similarly, meta‐analysis of IPD showed no significant treatment effect on any of the vascular outcomes studied; no effect was evident when PWV analyses were confined to studies using carotid‐femoral PWV. The main results for IPD analysis are shown in Table [6](#jah33189-tbl-0006){ref-type="table"}. For most analyses, heterogeneity as shown by the I^2^ statistic was low to moderate. Prespecified subgroup analysis of IPD data for each vascular outcome (Tables [7](#jah33189-tbl-0007){ref-type="table"}, [8](#jah33189-tbl-0008){ref-type="table"}, [9](#jah33189-tbl-0009){ref-type="table"}, [10](#jah33189-tbl-0010){ref-type="table"}, [11](#jah33189-tbl-0011){ref-type="table"}, [12](#jah33189-tbl-0012){ref-type="table"} through [13](#jah33189-tbl-0013){ref-type="table"}) did not show any subgroup consistently deriving significant benefit from vitamin D or analogues; treatment/subgroup interaction analyses suggested that participants with eGFR \<60 mL/min per 1.73 m^2^ may be less likely to show improvements in FMD or aortic diastolic BP with treatment, and those with 25(OH)D levels \<25 nmol/L may be more likely to show improvements in reactive hyperemia index and AIx with treatment. Participants with diabetes mellitus appeared to have a significantly greater rise in aortic BP than those without diabetes mellitus. For outcomes in both trial‐level and IPD analysis that were performed using SMD, standardizing SDs are given in Table [14](#jah33189-tbl-0014){ref-type="table"} to facilitate interpretation at the individual trial level.

###### 

IPD Analysis of Effect Size: Vitamin D Supplementation and Markers of Vascular Function

  Outcome                           No. of Studies   n      Mean Baseline Value Across All Groups (SD)   Random Effects          Fixed Effects   I^2^                           
  --------------------------------- ---------------- ------ -------------------------------------------- ----------------------- --------------- ----------------------- ------ -----
  FMD (%)                           10               655    5.6 (3.6)                                    −0.03 (−0.78 to 0.71)   0.93            −0.17 (−0.58 to 0.25)   0.44   63%
  AIx (%)                           11               832    27 (16)                                      0.1 (−1.4 to 1.6)       0.91            0.0 (−1.0 to 1.1)       0.96   39%
  RHI, units                        3                220    1.65 (0.81)                                  −0.02 (−0.12 to 0.08)   0.68            −0.02 (−0.12 to 0.08)   0.68   0%
  PWV (all; SMD)                    13               1154   ND                                           −0.01 (−0.16 to 0.13)   0.85            −0.04 (−0.15 to 0.08)   0.56   25%
  PWV (carotid‐femoral only; m/s)   9                652    7.9 (2.8)                                    −0.01 (−0.31 to 0.30)   0.96            −0.04 (−0.25 to 0.17)   0.70   44%
  PWV (others; SMD)                 4                502    ND                                           −0.02 (−0.20 to 0.16)   0.83            −0.05 (−0.36 to 0.26)   0.75   0%
  Microvascular function (SMD)      3                129    ND                                           0.36 (0.01--0.71)       0.05            0.36 (0.01--0.71)       0.13   0%
  Central SBP, mm Hg                7                400    120.7 (23.9)                                 −0.6 (−3.2 to 1.9)      0.63            −0.4 (−2.4 to 1.6)      0.67   31%
  Central DBP, mm Hg                7                400    76.5 (9.9)                                   −0.4 (−1.5 to 0.7)      0.48            −0.4 (−1.5 to 0.7)      0.48   0%

AIx indicates augmentation index; CI, confidence interval; DBP, diastolic blood pressure; FMD, flow‐mediated dilatation of the brachial artery; IPD, individual participant data; ND, not done because of heterogeneity of measurement methods; PWV, pulse wave velocity; RHI, reactive hyperemia index; SBP, systolic blood pressure; SMD, standardized mean difference.

###### 

IPD Subgroup Analyses for FMD

  Subgroup                                                                 No. of Studies   n     Mean Baseline Value (%) (SD)   Random Effects        Fixed Effects   I^2^                                                       
  ------------------------------------------------------------------------ ---------------- ----- ------------------------------ --------------------- --------------- -------------------- --------------------- ------- ------- -----
  SBP \>140 mm Hg                                                          9                242   5.2 (3.2)                      0.0 (−1.1 to 1.0)     0.94            0.88                 −0.1 (−0.6 to 0.5)    0.82    1.0     56%
  SBP ≤140 mm Hg                                                           9                376   5.9 (3.8)                      0.1 (−0.9 to 1.0)     0.90            −0.1 (−0.6 to 0.5)   0.79                  58%             
  Baseline 25(OH)D \<25 nmol/L                                             6                89    5.7 (4.0)                      −0.3 (−1.8 to 1.2)    0.65            ···                  −0.1 (−1.0 to 0.9)    0.92    ···     43%
  Baseline 25(OH)D 25 to 50 nmol/L                                         9                292   5.3 (3.3)                      −0.1 (−1.2 to 1.0)    0.87            0.83                 −0.1 (−0.7 to 0.5)    0.66    1.0     66%
  Baseline 25(OH)D \>50 nmol/L                                             8                222   5.4 (3.4)                      −0.2 (−1.1 to 0.7)    0.66            0.91                 −0.2 (−0.9 to 0.4)    0.47    0.87    41%
  DM                                                                       6                198   5.2 (3.5)                      0.1 (−1.1 to 1.4)     0.82            0.47                 0.4 (−0.5 to 1.2)     0.40    0.27    37%
  No DM                                                                    7                454   5.7 (3.5)                      −0.4 (−0.9 to 0.1)    0.14            −0.3 (−1.2 to 0.6)   0.55                  63%             
  No ACEi or ARB                                                           9                254   6.5 (3.6)                      0.1 (−2.0 to 2.2)     0.92            ···                  −0.6 (−1.3 to 0.1)    0.09    ···     88%
  ACEi, no ARB                                                             7                171   5.4 (3.5)                      −0.4 (−1.7 to 1.0)    0.58            0.69                 −0.2 (−1.0 to 0.6)    0.64    0.46    47%
  ACEi or ARB                                                              7                297   5.0 (3.4)                      −0.7 (−1.9 to 0.5)    0.28            0.52                 −0.7 (−1.4 to −0.1)   0.03    0.84    60%
  PTH \>5.0 pmol/L                                                         8                254   5.4 (3.6)                      −0.3 (−1.5 to 0.9)    0.61            0.39                 −0.8 (−1.5 to −0.2)   0.02    0.02    62%
  PTH ≤5.0 pmol/L                                                          7                230   5.7 (3.1)                      0.3 (−0.3 to 1.0)     0.30            0.3 (−0.3 to 1.0)    0.30                  0%              
  Ca \>2.30 mmol/L                                                         7                226   6.0 (3.4)                      0.3 (−0.3 to 1.0)     0.30            0.19                 0.3 (−0.3 to 1.0)     0.30    0.08    0%
  Ca ≤2.30 mmol/L                                                          7                371   5.2 (3.4)                      −0.5 (−1.5 to 0.5)    0.30            −0.5 (−1.1 to 0.1)   0.09                  56%             
  eGFR ≥60 mL/min per 1.73 m^2^                                            6                382   5.6 (3.4)                      0.5 (−0.2 to 1.2)     0.18            ···                  0.6 (0.0--1.2)        0.04    ···     27%
  eGFR 45 to 59 mL/min per 1.73 m^2^                                       5                59    5.3 (3.1)                      −0.1 (−2.2 to 2.1)    0.94            0.60                 0.3 (−1.0 to 1.5)     0.66    0.67    55%
  eGFR 30 to 44 mL/min per 1.73 m^2^                                       3                38    4.5 (2.9)                      −1.0 (−2.7 to 0.7)    0.27            0.11                 −1.0 (−2.7 to 0.7)    0.27    0.08    0%
  eGFR 15 to 29 mL/min per 1.73 m^2^                                       1                24    3.4 (3.0)                      −3.1 (−5.7 to −0.5)   0.02            0.009                −3.1 (−5.7 to −0.5)   0.02    0.007   ···
  eGFR \<15 mL/min per 1.73 m^2^ [a](#jah33189-note-0010){ref-type="fn"}   0                ···   ···                            ···                   ···             ···                  ···                   ···     ···     ···
  Total cholesterol ≥4.60 mmol/L                                           8                223   5.4 (3.4)                      −0.9 (−1.9 to 0.1)    0.07            0.23                 −1.0 (−1.6 to −0.4)   0.002   0.06    51%
  Total cholesterol \<4.60 mmol/L                                          8                283   5.6 (3.7)                      0.1 (−1.1 to 1.4)     0.83            −0.2 (−0.8 to 0.4)   0.60                  69%             

25(OH)D indicates 25‐hydroxyvitamin D; ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FMD, flow‐mediated dilatation of the brachial artery; IPD, individual participant data; PTH, parathyroid hormone; SBP, systolic blood pressure.

Or on dialysis.

###### 

IPD Subgroup Analyses for PWV

  Subgroup                                                                 No. of Studies   N      Mean Baseline Value (m/s) (SD)[a](#jah33189-note-0012){ref-type="fn"}   Random Effects       Fixed Effects   I^2^                                                    
  ------------------------------------------------------------------------ ---------------- ------ ----------------------------------------------------------------------- -------------------- --------------- -------------------- -------------------- ------ ------ -----
  SBP \>140 mm Hg                                                          9                396    8.9 (3.2)                                                               −0.1 (−0.3 to 0.1)   0.21            0.49                 −0.1 (−0.3 to 0.1)   0.21   0.43   0%
  SBP ≤140 mm Hg                                                           11               728    7.5 (2.6)                                                               0.0 (−0.2 to 0.2)    1.00            −0.0 (−0.2 to 0.1)   0.62                 40%           
  Baseline 25(OH)D \<25 nmol/L                                             11               157    7.6 (2.8)                                                               0.2 (−0.2 to 0.5)    0.36            ···                  0.2 (−0.2 to 0.5)    0.36   ···    0%
  Baseline 25(OH)D 25 to 50 nmol/L                                         12               508    8.0 (3.2)                                                               −0.1 (−0.3 to 0.2)   0.67            0.17                 −0.1 (−0.3 to 0.1)   0.38   0.15   39%
  Baseline 25(OH)D \>50 nmol/L                                             10               482    7.8 (2.6)                                                               0.0 (−0.2 to 0.2)    0.81            0.33                 0.0 (−0.2 to 0.2)    0.76   0.33   12%
  DM                                                                       6                130    8.5 (4.5)                                                               0.1 (−0.3 to 0.4)    0.65            0.30                 0.1 (−0.3 to 0.4)    0.65   0.30   0%
  No DM                                                                    13               1021   7.8 (2.5)                                                               −0.1 (−0.2 to 0.1)   0.32            −0.1 (−0.2 to 0.1)   0.32                 0%            
  No ACEi or ARB                                                           9                399    7.7 (3.1)                                                               −0.1 (−0.3 to 0.2)   0.70            ···                  −0.1 (−0.3 to 0.1)   0.44   ···    21%
  ACEi, no ARB                                                             7                203    8.5 (3.3)                                                               −0.2 (−0.5 to 0.1)   0.17            0.62                 −0.2 (−0.5 to 0.1)   0.17   0.62   0%
  ACEi or ARB                                                              8                364    8.1 (3.2)                                                               0.0 (−0.3 to 0.2)    0.68            0.58                 0.0 (−0.3 to 0.2)    0.68   0.58   0%
  PTH \>5.0 pmol/L                                                         12               482    7.9 (2.9)                                                               −0.1 (−0.3 to 0.1)   0.16            0.49                 −0.1 (−0.3 to 0.1)   0.16   0.49   0%
  PTH ≤5.0 pmol/L                                                          12               594    7.9 (3.2)                                                               0.0 (−0.2 to 0.2)    0.97            0.0 (−0.2 to 0.2)    0.95                 12%           
  Ca \>2.30 mmol/L                                                         9                456    7.8 (3.5)                                                               0.0 (−0.2 to 0.2)    0.91            0.12                 0.0 (−0.2 to 0.2)    0.91   0.12   0%
  Ca ≤2.30 mmol/L                                                          10               496    8.0 (2.6)                                                               −0.2 (−0.3 to 0.0)   0.11            −0.2 (−0.3 to 0.0)   0.10                 2%            
  eGFR ≥60 mL/min per 1.73 m^2^                                            10               897    7.8 (2.3)                                                               0.0 (−0.2 to 0.1)    0.57            ···                  0.0 (−0.2 to 0.1)    0.55   ···    5%
  eGFR 45 to 59 mL/min per 1.73 m^2^                                       6                76     7.2 (4.8)                                                               0.3 (−0.3 to 0.9)    0.35            0.34                 0.2 (−0.3 to 0.7)    0.41   0.45   12%
  eGFR 30 to 44 mL/min per 1.73 m^2^                                       3                27     8.8 (2.0)                                                               −0.8 (−1.6 to 0.1)   0.07            0.07                 −0.8 (−1.6 to 0.1)   0.07   0.07   0%
  eGFR 15 to 29 mL/min per 1.73 m^2^                                       2                8      13.7 (1.1)                                                              0.1 (−2.0 to 2.2)    0.95            0.93                 0.1 (−2.0 to 2.2)    0.95   0.93   0%
  eGFR \<15 mL/min per 1.73 m^2^ [b](#jah33189-note-0013){ref-type="fn"}   2                54     9.0 (4.9)                                                               0.4 (−0.1 to 1.0)    0.12            0.17                 0.4 (−0.1 to 1.0)    0.12   0.17   0%
  Total cholesterol ≥4.60 mmol/L                                           11               651    7.8 (2.3)                                                               −0.1 (−0.3 to 0.1)   0.24            0.54                 −0.1 (−0.3 to 0.1)   0.24   0.49   0%
  Total cholesterol \<4.60 mmol/L                                          11               398    7.7 (3.0)                                                               0.0 (−0.2 to 0.3)    0.83            0.0 (−0.2 to 0.2)    0.87                 23%           

25(OH)D indicates 25‐hydroxyvitamin D; ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IPD, individual participant data; PTH, parathyroid hormone; PWV, pulse wave velocity; SBP, systolic blood pressure; SMD, standardized mean difference.

Data only from studies measuring baseline carotid‐femoral PWV.

Or on dialysis.

###### 

IPD Subgroup Analyses for AIx

  Subgroup                                                                 No. of Studies   n     Mean Baseline Value (%) (SD)   Random Effects        Fixed Effects   I^2^                                                              
  ------------------------------------------------------------------------ ---------------- ----- ------------------------------ --------------------- --------------- -------------------- ------------------------ --------- --------- -----
  SBP \>140 mm Hg                                                          9                214   33.3 (16.6)                    0.8 (−1.1 to 2.7)     0.39            0.31                 0.8 (−1.1 to 2.7)        0.39      0.26      0%
  SBP ≤140 mm Hg                                                           11               615   24.9 (14.6)                    −0.6 (−2.5 to 1.4)    0.57            −0.5 (−1.7 to 0.7)   0.44                     52%                 
  Baseline 25(OH)D \<25 nmol/L                                             8                93    24.9 (14.9)                    −4.3 (−11.0 to 2.4)   0.20            ···                  −4.8 (−7.8 to −1.7)      0.002     ···       76%
  Baseline 25(OH)D 25 to 50 nmol/L                                         10               357   25.8 (16.7)                    0.1 (−1.9 to 2.1)     0.92            0.22                 0.0 (−1.5 to 1.5)        0.99      0.006     30%
  Baseline 25(OH)D \>50 nmol/L                                             8                342   28.6 (15.2)                    0.5 (−1.1 to 2.0)     0.58            0.17                 0.5 (−1.1 to 2.0)        0.58      0.002     0%
  DM                                                                       7                163   26.1 (15.6)                    2.0 (−2.6 to 6.6)     0.40            0.37                 0.4 (−2.2 to 3.1)        0.75      0.68      61%
  No DM                                                                    9                666   27.3 (15.7)                    −0.2 (−1.4 to 1.1)    0.80            −0.2 (−1.3 to 0.9)   0.73                     11%                 
  No ACEi or ARB                                                           9                209   23.1 (14.3)                    −0.2 (−2.0 to 1.7)    0.86            ···                  −0.2 (−2.0 to 1.6)       0.85      ···       4%
  ACEi, no ARB                                                             7                137   25.4 (12.6)                    0.3 (−1.6 to 2.2)     0.79            0.71                 0.3 (−1.6 to 2.2)        0.79      0.71      0%
  ACEi or ARB                                                              7                243   26.4 (12.7)                    −0.1 (−2.1 to 1.9)    0.94            0.94                 −0.4 (−1.9 to 1.2)       0.63      0.87      27%
  PTH \>5.0 pmol/L                                                         9                282   25.3 (15.9)                    0.1 (−2.4 to 2.5)     0.96            0.89                 −0.3 (−2.1 to 1.5)       0.73      0.62      43%
  PTH ≤5.0 pmol/L                                                          9                441   27.9 (16.9)                    0.3 (−1.3 to 1.8)     0.72            0.3 (−1.3 to 1.8)    0.72                     0%                  
  Ca \>2.30 mmol/L                                                         5                286   28.3 (18.7)                    0.0 (−3.6 to 3.6)     1.00            0.45                 −0.1 (−3.4 to 3.2)       0.96      0.39      11%
  Ca ≤2.30 mmol/L                                                          6                265   26.2 (13.3)                    1.6 (−0.4 to 3.6)     0.12            1.6 (−0.4 to 3.6)    0.12                     0%                  
  eGFR ≥60 mL/min per 1.73 m^2^                                            9                678   27.3 (15.7)                    −0.3 (−1.7 to 1.2)    0.34            ···                  −0.2 (−1.4 to 0.9)       0.72      ···       25%
  eGFR 45 to 59 mL/min per 1.73 m^2^                                       6                64    28.3 (16.7)                    −5.4 (−11.7 to 0.9)   0.09            0.36                 −11.7 (−12.2 to −11.3)   \<0.001   \<0.001   86%
  eGFR 30 to 44 mL/min per 1.73 m^2^                                       2                17    29.7 (18.2)                    −0.8 (−8.8 to 7.2)    0.85            0.43                 −0.8 (−8.8 to 7.2)       0.85      0.88      0%
  eGFR 15 to 29 mL/min per 1.73 m^2^                                       0                ···   ···                            ···                   ···             ···                  ···                      ···       ···       ···
  eGFR \<15 mL/min per 1.73 m^2^ [a](#jah33189-note-0015){ref-type="fn"}   2                51    22.9 (12.8)                    6.6 (2.1--11.2)       0.005           0.40                 6.6 (2.1--11.2)          0.005     0.005     0%
  Total cholesterol ≥4.60 mmol/L                                           9                434   27.8 (15.6)                    −0.5 (−2.7 to 1.7)    0.66            0.95                 0.0 (−1.4 to 1.5)        1.00      0.61      39%
  Total cholesterol \<4.60 mmol/L                                          9                298   26.4 (16.2)                    −0.4 (−2.5 to 1.7)    0.73            −0.6 (−2.4 to 1.2)   0.52                     20%                 

25(OH)D indicates 25‐hydroxyvitamin D; ACEi, angiotensin‐converting enzyme inhibitor; Aix, augmentation index; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IPD, individual participant data; PTH, parathyroid hormone; SBP, systolic blood pressure.

Or on dialysis.

###### 

IPD Subgroup Analyses for RHI

  Subgroup                           No. of Studies   n     Mean Baseline Value (Units) (SD)   Random Effects          Fixed Effects   I^2^                                                                
  ---------------------------------- ---------------- ----- ---------------------------------- ----------------------- --------------- ----------------------- ----------------------- --------- --------- -----
  SBP \>140 mm Hg                    3                73    1.71 (0.94)                        −0.21 (−0.52 to 0.10)   0.18            0.21                    −0.14 (−0.33 to 0.05)   0.16      0.20      49%
  SBP ≤140 mm Hg                     3                147   1.62 (0.74)                        0.01 (0.11--0.14)       0.85            0.01 (0.11--0.14)       0.85                    0%                  
  Baseline 25(OH)D \<25 nmol/L       1                21    1.82 (0.68)                        0.23 (−0.10 to 0.56)    0.18            ···                     0.23 (−0.10 to 0.56)    0.18      ···       ···
  Baseline 25(OH)D 25 to 50 nmol/L   3                153   1.71 (0.83)                        −0.02 (−0.19 to 0.16)   0.86            0.19                    0.02 (−0.09 to 0.14)    0.67      0.24      46%
  Baseline 25(OH)D \>50 nmol/L       2                40    1.33 (0.76)                        −0.21 (−0.42 to 0.00)   0.05            0.03                    −0.21 (−0.42 to 0.00)   0.05      0.03      0%
  DM                                 3                110   1.23 (0.74)                        0.01 (−0.10 to 0.11)    0.91            0.17                    0.01 (−0.10 to 0.11)    0.91      0.17      0%
  No DM                              2                101   2.07 (0.63)                        −0.15 (−0.35 to 0.06)   0.16            −0.15 (−0.35 to 0.06)   0.16                    0%                  
  No ACEi or ARB                     3                49    1.57 (0.79)                        0.42 (−0.72 to 1.57)    0.47            ···                     0.47 (0.29 to 0.66)     \<0.001   ···       97%
  ACEi, no ARB                       3                128   1.75 (0.82)                        −0.00 (−0.16 to 0.15)   0.96            0.48                    −0.00 (−0.14 to 0.13)   0.96      \<0.001   27%
  ACEi or ARB                        3                171   1.67 (0.81)                        −0.05 (−0.21 to 0.11)   0.54            0.43                    −0.04 (−0.15 to 0.07)   0.50      \<0.001   46%
  PTH \>5.0 pmol/L                   3                117   1.77 (0.77)                        −0.02 (−0.17 to 0.13)   0.80            0.85                    −0.02 (−0.17 to 0.13)   0.80      0.85      0%
  PTH ≤5.0 pmol/L                    3                102   1.52 (0.84)                        0.00 (−0.14 to 0.14)    1.00            0.00 (−0.14 to 0.14)    1.00                    0%                  
  Ca \>2.30 mmol/L                   3                127   1.50 (0.81)                        −0.08 (−0.21 to 0.05)   0.21            0.22                    −0.08 (−0.21 to 0.05)   0.21      0.22      0%
  Ca ≤2.30 mmol/L                    3                93    1.86 (0.76)                        0.05 (−0.11 to 0.21)    0.55            0.05 (−0.11 to 0.21)    0.55                    0%                  
  eGFR ≥60 mL/min per 1.73 m^2^      3                192   1.69 (0.80)                        −0.04 (−0.14 to 0.07)   0.48            0.81                    −0.04 (−0.14 to 0.07)   0.48      0.77      0%
  eGFR \<60 mL/min per 1.73 m^2^     2                27    1.41 (0.84)                        −0.10 (−0.58 to 0.39)   0.69            0.00 (−0.25 to 0.25)    1.00                    54%                 
  Total cholesterol ≥4.60 mmol/L     3                60    1.44 (0.85)                        −0.04 (−0.38 to 0.30)   0.81            1.00                    0.00 (−0.19 to 0.18)    0.98      0.73      43%
  Total cholesterol \<4.60 mmol/L    3                141   1.72 (0.81)                        −0.04 (−0.16 to 0.09)   0.57            −0.04 (−0.16 to 0.09)   0.57                    0%                  

25(OH)D indicates 25‐hydroxyvitamin D; ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IPD, individual participant data; PTH, parathyroid hormone; RHI, reactive hyperemia index; SBP, systolic blood pressure.

###### 

IPD Subgroup Analyses for Microvascular Function

  Subgroup                           No. of Studies   n     Random Effects          Fixed Effects   I^2^                                                         
  ---------------------------------- ---------------- ----- ----------------------- --------------- ---------------------- ----------------------- ------ ------ -----
  SBP \>140 mm Hg                    1                21    0.08 (−0.80 to 0.96)    0.86            0.47                   0.08 (−0.80 to 0.96)    0.86   0.47   ···
  SBP ≤140 mm Hg                     3                106   0.44 (0.05--0.82)       0.03            0.44 (0.05--0.82)      0.03                    0%            
  Baseline 25(OH)D \<25 nmol/L       3                46    0.05 (−0.54 to 0.64)    0.86            ···                    0.05 (−0.54 to 0.64)    0.86   ···    0%
  Baseline 25(OH)D 25 to 50 nmol/L   3                56    0.20 (−0.39 to 0.79)    0.51            0.72                   0.20 (−0.34 to 0.74)    0.47   0.71   11%
  Baseline 25(OH)D \>50 nmol/L       2                26    1.04 (0.14--1.93)       0.02            0.04                   1.04 (0.14--1.93)       0.02   0.04   0%
  DM                                 1                18    0.41 (−0.54 to 1.35)    0.40            0.91                   0.41 (−0.54 to 1.35)    0.40   0.91   ···
  No DM                              3                111   0.35 (−0.03 to 0.73)    0.07            0.35 (−0.03 to 0.73)   0.07                    0%            
  No ACEi or ARB                     2                70    0.19 (−0.28 to 0.66)    0.44            ···                    0.19 (−0.28 to 0.66)    0.44   ···    0%
  ACEi, no ARB                       2                29    0.37 (−0.38 to 1.13)    0.33            0.69                   0.37 (−0.38 to 1.13)    0.33   0.69   0%
  ACEi or ARB                        2                57    0.65 (0.11--1.18)       0.02            0.21                   0.65 (0.11--1.18)       0.02   0.21   0%
  PTH \>5.0 pmol/L                   3                70    0.24 (−0.24 to 0.72)    0.33            0.54                   0.24 (−0.24 to 0.72)    0.33   0.54   0%
  PTH ≤5.0 pmol/L                    2                54    0.47 (−0.08 to 1.02)    0.09            0.47 (−0.08 to 1.02)   0.09                    0%            
  Ca \>2.30 mmol/L                   2                25    −0.45 (−1.25 to 0.35)   0.27            0.10                   −0.45 (−1.25 to 0.35)   0.27   0.10   0%
  Ca ≤2.30 mmol/L                    2                37    0.43 (−0.23 to 1.09)    0.20            0.43 (−0.23 to 1.09)   0.20                    0%            
  eGFR ≥60 mL/min per 1.73 m^2^      2                86    0.22 (−0.21 to 0.64)    0.32            0.46                   0.22 (−0.21 to 0.64)    0.32   0.46   0%
  eGFR \<60 mL/min per 1.73 m^2^     2                43    0.50 (−0.11 to 1.11)    0.11            0.50 (−0.11 to 1.11)   0.11                    0%            
  Total cholesterol ≥4.60 mmol/L     3                66    0.05 (−0.47 to 0.57)    0.85            0.32                   0.05 (−0.45 to 0.54)    0.85   0.31   7%
  Total cholesterol \<4.60 mmol/L    3                61    0.42 (−0.10 to 0.94)    0.11            0.42 (−0.10 to 0.94)   0.11                    0%            

25(OH)D indicates 25‐hydroxyvitamin D; ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IPD, individual participant data; PTH, parathyroid hormone; SBP, systolic blood pressure; SMD, standardized mean difference.

###### 

IPD Subgroup Analyses for Aortic SBP

  Subgroup                           No. of Studies   n     Mean Baseline Value (mm Hg) (SD)   Random Effects         Fixed Effects   I^2^                                                          
  ---------------------------------- ---------------- ----- ---------------------------------- ---------------------- --------------- --------------------- --------------------- --------- ------- -----
  SBP \>140 mm Hg                    5                79    141.4 (26.3)                       0.4 (−8.8 to 9.6)      0.93            0.95                  0.4 (−5.5 to 6.3)     0.90      0.82    57%
  SBP ≤140 mm Hg                     7                319   115.8 (19.1)                       0.1 (−3.3 to 3.5)      0.96            −0.3 (−2.4 to 1.9)    0.82                  51%               
  Baseline 25(OH)D \<25 nmol/L       6                77    114.2 (28.7)                       −2.7 (−9.8 to 4.4)     0.46            ···                   −1.7 (−5.9 to 2.5)    0.42      ···     50%
  Baseline 25(OH)D 25 to 50 nmol/L   7                148   121.9 (24.7)                       −2.9 (−6.0 to 0.3)     0.08            0.96                  −2.9 (−6.0 to 0.3)    0.08      0.65    0%
  Baseline 25(OH)D \>50 nmol/L       6                171   123.0 (20.1)                       0.7 (−3.8 to 5.1)      0.76            0.43                  1.2 (−1.9 to 4.2)     0.45      0.27    24%
  DM                                 4                45    119.3 (35.3)                       9.4 (−0.2 to 19.1)     0.06            0.17                  7.9 (0.3 to 15.4)     0.04      0.006   26%
  No DM                              7                355   120.9 (22.0)                       −1.6 (−13.8 to 10.6)   0.80            −3.0 (−5.1 to −1.0)   0.004                 97%               
  No ACEi or ARB                     5                138   111.8 (24.1)                       −6.1 (−11.8 to −0.4)   0.04            ···                   −5.8 (−9.1 to −2.1)   \<0.001   ···     51%
  ACEi, no ARB                       3                78    130.4 (22.1)                       −5.4 (−10.8 to 0.1)    0.05            0.87                  −5.4 (−10.8 to 0.1)   0.05      0.9     0%
  ACEi or ARB                        4                173   132.6 (23.7)                       −3.1 (−7.1 to 0.8)     0.12            0.40                  −3.1 (−7.1 to 0.8)    0.12      0.32    0%
  PTH \>5.0 pmol/L                   6                168   121.0 (27.5)                       −1.0 (−4.3 to 2.3)     0.55            0.52                  −1.0 (−4.3 to 2.3)    0.55      0.67    0%
  PTH ≤5.0 pmol/L                    6                154   123.1 (24.0)                       2.8 (−8.2 to 13.8)     0.62            −1.9 (−5.6 to 1.8)    0.31                  85%               
  Ca \>2.30 mmol/L                   2                30    118.4 (20.0)                       0.3 (−5.5 to 6.0)      0.93            0.61                  0.3 (−5.5 to 6.0)     0.93      0.61    0%
  Ca ≤2.30 mmol/L                    3                120   121.9 (25.9)                       2.0 (−0.9 to 5.0)      0.18            2.0 (−0.9 to 5.0)     0.18                  0%                
  eGFR ≥60 mL/min per 1.73 m^2^      5                300   120.0 (17.7)                       −1.3 (−4.8 to 2.2)     0.47            0.70                  −0.6 (−2.8 to 1.5)    0.56      0.92    59%
  eGFR \<60 mL/min per 1.73 m^2^     4                44    130.9 (20.2)                       0.8 (−9.2 to 10.9)     0.87            −0.9 (−6.3 to 4.6)    0.76                  69%               
  Total cholesterol ≥4.60 mmol/L     5                158   122.2 (21.6)                       −2.3 (−5.8 to 1.2)     0.20            0.68                  −2.3 (−5.8 to 1.2)    0.20      0.76    0%
  Total cholesterol \<4.60 mmol/L    5                138   122.5 (27.5)                       −0.7 (−7.5 to 6.1)     0.83            −1.5 (−5.3 to 2.4)    0.45                  66%               

25(OH)D indicates 25‐hydroxyvitamin D; ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IPD, individual participant data; PTH, parathyroid hormone; SBP, systolic blood pressure.

###### 

IPD Subgroup Analyses for Aortic DBP

  Subgroup                           No. of Studies   n     Mean Baseline Value (mm Hg) (SD)   Random Effects       Fixed Effects   I^2^                                                    
  ---------------------------------- ---------------- ----- ---------------------------------- -------------------- --------------- -------------------- -------------------- ------ ------ -----
  SBP \>140 mm Hg                    5                79    79.8 (11.1)                        −0.7 (−3.3 to 2.0)   0.62            0.95                 −0.7 (−3.3 to 2.0)   0.62   0.95   0%
  SBP ≤140 mm Hg                     7                320   75.7 (9.3)                         −0.6 (−1.9 to 0.6)   0.33            −0.6 (−1.9 to 0.6)   0.33                 0%            
  Baseline 25(OH)D \<25 nmol/L       6                77    75.8 (9.5)                         1.0 (−2.4 to 4.5)    0.56            ···                  1.0 (−2.4 to 4.5)    0.56   ···    0%
  Baseline 25(OH)D 25 to 50 nmol/L   7                151   77.2 (10.0)                        −0.7 (−2.8 to 1.3)   0.48            0.41                 −0.7 (−2.8 to 1.3)   0.48   0.41   0%
  Baseline 25(OH)D \>50 nmol/L       6                171   76.3 (10.0)                        −0.5 (−2.0 to 1.0)   0.52            0.43                 −0.5 (−2.0 to 1.0)   0.52   0.43   0%
  DM                                 4                45    74.0 (11.5)                        3.8 (−1.6 to 9.1)    0.17            0.12                 2.8 (0.1 to 5.4)     0.04   0.02   68%
  No DM                              7                355   76.9 (9.6)                         −0.6 (−1.9 to 0.6)   0.29            −0.6 (−1.9 to 0.6)   0.29                 0%            
  No ACEi or ARB                     6                152   75.4 (9.8)                         −0.5 (−2.6 to 1.5)   0.61            ···                  −0.5 (−2.6 to 1.5)   0.61   ···    0%
  ACEi, no ARB                       4                92    79.3 (11.4)                        0.6 (−1.9 to 3.1)    0.62            0.50                 0.6 (−1.9 to 3.1)    0.62   0.50   0%
  ACEi or ARB                        4                173   78.4 (10.5)                        −0.4 (−2.2 to 1.4)   0.69            0.94                 −0.4 (−2.2 to 1.4)   0.69   0.94   0%
  PTH \>5.0 pmol/L                   6                169   77.3 (10.2)                        0.1 (−2.3 to 2.5)    0.93            0.62                 0.1 (−2.3 to 2.5)    0.93   0.59   0%
  PTH ≤5.0 pmol/L                    6                154   77.2 (10.4)                        −0.7 (−2.7 to 1.3)   0.52            −0.7 (−2.4 to 1.0)   0.39                 17%           
  Ca \>2.30 mmol/L                   2                31    79.3 (9.8)                         0.4 (−4.7 to 5.5)    0.88            0.94                 0.4 (−4.7 to 5.5)    0.88   0.94   0%
  Ca ≤2.30 mmol/L                    3                120   77.0 (10.2)                        0.2 (−1.6 to 1.9)    0.86            0.2 (−1.6 to 1.9)    0.86                 0%            
  eGFR ≥60 mL/min per 1.73 m^2^      5                300   77.3 (9.2)                         −0.6 (−1.8 to 0.7)   0.35            0.07                 −0.6 (−1.8 to 0.7)   0.35   0.03   0%
  eGFR \<60 mL/min per 1.73 m^2^     4                45    75.5 (9.2)                         4.6 (−0.9 to 10.1)   0.10            2.9 (−0.1 to 5.9)    0.06                 46%           
  Total cholesterol ≥4.60 mmol/L     5                158   77.3 (9.5)                         −0.6 (−2.6 to 1.3)   0.52            0.76                 −0.6 (−2.6 to 1.3)   0.52   0.89   0%
  Total cholesterol \<4.60 mmol/L    5                138   74.5 (9.8)                         0.0 (−3.3 to 3.4)    0.98            −0.8 (−3.0 to 1.3)   0.45                 49%           

25(OH)D indicates 25‐hydroxyvitamin D; ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IPD, individual participant data; PTH, parathyroid hormone; SBP, systolic blood pressure.

###### 

Standardizing SDs Pertaining to Trials Combined Using SMD Method

  Study                                                       Trial Level   IPD (Pooled SD)         
  ----------------------------------------------------------- ------------- ----------------- ----- ------
  Gepner 2012[15](#jah33189-bib-0015){ref-type="ref"}         0.9, 1.1      ···               1.0   ···
  Larsen 2012[16](#jah33189-bib-0016){ref-type="ref"}         0.9, 1.4      ···               1.2   ···
  Marckmann 2012[17](#jah33189-bib-0017){ref-type="ref"}      2.6, 2.6      ···               3.1   ···
  Stricker 2012[19](#jah33189-bib-0019){ref-type="ref"}       ···           16.4, 12.4        ···   13.4
  Hewitt 2013[22](#jah33189-bib-0022){ref-type="ref"}         5.3, 4.8      ···               ···   ···
  Witham 2013[23](#jah33189-bib-0023){ref-type="ref"}         1.4, 1.3      ···               1.2   ···
  Witham 2013[25](#jah33189-bib-0025){ref-type="ref"}         1.2, 1.6      1.1, 3.3          1.2   1.8
  Yiu 2013[26](#jah33189-bib-0026){ref-type="ref"}            3.4, 4.1      ···               ···   ···
  Dreyer 2014[27](#jah33189-bib-0027){ref-type="ref"}         1.1, 0.8      727, 391          1.0   591
  Mose 2014[29](#jah33189-bib-0029){ref-type="ref"}           2.1, 2.4      ···               2.3   ···
  Ryu 2014[30](#jah33189-bib-0030){ref-type="ref"}            1.4, 1.8      ···               ···   ···
  Garg 2015[32](#jah33189-bib-0032){ref-type="ref"}           1.3, 1.2      ···               1.1   ···
  Pilz 2015[33](#jah33189-bib-0033){ref-type="ref"}           1.6, 1.6      ···               1.9   ···
  Witham 2015[35](#jah33189-bib-0035){ref-type="ref"}         2.5, 1.6      ···               0.9   ···
  Bressendorff 2016[38](#jah33189-bib-0038){ref-type="ref"}   0.9, 0.4      ···               1.1   ···
  Forouhi 2016[40](#jah33189-bib-0040){ref-type="ref"}        2.1, 1.7      ···               1.7   ···
  Hin 2017[41](#jah33189-bib-0041){ref-type="ref"}            1.4, 1.4      ···               3.7   ···

IPD indicates individual participant data; PWV, pulse wave velocity; SMD, standardized mean difference.

Discussion {#jah33189-sec-0021}
==========

The present meta‐analysis found little evidence to support the hypothesis that supplementation of vitamin D or use of vitamin D analogues can improve markers of cardiovascular health. Our results were broadly consistent across a range of vascular markers and interventions, and subgroup analyses using IPD did not identify a subgroup that was more likely to benefit from treatment---this remained true even for those participants with the lowest 25(OH)D levels, with high baseline BP, and with higher baseline PTH levels. Random‐effects and fixed‐effects analyses gave very similar results in the majority of analyses. Our results are consistent with our previous work that failed to find a beneficial effect of vitamin D therapy on BP[5](#jah33189-bib-0005){ref-type="ref"} and are also in accord with 2 recent, smaller meta‐analyses examining arterial stiffness and endothelial function.[42](#jah33189-bib-0042){ref-type="ref"}, [43](#jah33189-bib-0043){ref-type="ref"} One further recent meta‐analysis, examining only FMD, showed a slightly greater benefit (treatment effect of vitamin D was 1.27% for FMD),[44](#jah33189-bib-0044){ref-type="ref"} perhaps attributable to differences in both study selection and the data used; our analysis had the benefit of access to IPD, which allowed us to verify the accuracy of published data and data used in previous meta‐analyses. The results are also consistent with recent data suggesting no effect of vitamin D supplementation on plasma N‐terminal pro‐B‐type natriuretic peptide levels or echocardiographic indices in older people after 12 months of therapy.[45](#jah33189-bib-0045){ref-type="ref"}

Despite the large number of participants included in this analysis, it is not possible to completely refute the possibility that vitamin D or its analogues could still have a modest benefit on vascular health. The markers measured in studies included in this meta‐analysis are subject to changes attributed to differences in environment, diet, smoking, medications, and operator skill; such factors require careful use of protocols to standardize measurement and reduce variability.[46](#jah33189-bib-0046){ref-type="ref"}, [47](#jah33189-bib-0047){ref-type="ref"} The upper limit of the 95% CIs in our analyses encompasses a 1% improvement in FMD, a 1% improvement in AIx, a 0.3‐m/s improvement in PWV, and a 5.6 mm Hg improvement in aortic systolic BP. A 5 mm Hg reduction in aortic systolic BP would be consistent with significant clinical benefit, and a 1% improvement in FMD would be consistent with an 8% to 13% reduction in cardiovascular event rates.[48](#jah33189-bib-0048){ref-type="ref"}, [49](#jah33189-bib-0049){ref-type="ref"} A trial published too recently to be included in this systematic review suggested a large improvement in FMD in participants with nondialyzed CKD,[50](#jah33189-bib-0050){ref-type="ref"} and it therefore remains possible that individuals with nondialyzed CKD, particularly with baseline low 25(OH)D levels, might benefit, although results from trials enrolling nondialyzed CKD participants that we included in this review showed improvement in FMD in only 1 of 3 trials.[11](#jah33189-bib-0011){ref-type="ref"}, [31](#jah33189-bib-0031){ref-type="ref"}, [34](#jah33189-bib-0034){ref-type="ref"} Similarly, a recently published substudy using monthly high‐dose vitamin D3 showed an improvement in aortic BP and arterial stiffness measures in those with baseline 25(OH)D levels \<50 nmol/L; effect sizes were consistent with our IPD analysis findings for this subgroup. No significant improvements were observed in the overall trial group, however.[51](#jah33189-bib-0051){ref-type="ref"}

Pooled observational data show that a log~e~ difference in PWV (≈2.7 m/s) corresponds to a 35% to 45% increase in the risk of a cardiovascular event. A 0.3‐m/s improvement in PWV is therefore unlikely to be associated with a clinically important reduction in cardiovascular events.[52](#jah33189-bib-0052){ref-type="ref"} Furthermore, it is still possible that agents such as paricalcitol might provide a greater magnitude of benefit to selected markers such as FMD. Paricalcitol is an active analogue of vitamin D (ie, it does not require further hydroxylation before binding to and activating the vitamin D receptor), and it is possible that this pharmacological difference from vitamin D2 or D3 might account for the observed result. It is, however, more likely that this result is attributed to the play of chance given the large number of comparisons contained in our analysis.

A modest improvement in microvascular function with vitamin D was noted in the trial‐level analysis, although this was of smaller magnitude in the IPD analyses and did not reach significance. The clinical significance of such an improvement in microvascular function is less clear than for changes in macrovascular markers, given that there are few long‐term prognostic studies evaluating microvascular markers. Differences in the physiological control of small and large blood vessels, particularly the role of local metabolic factors in determining microvascular tone, may underpin the difference in response to vitamin D observed here.

A number of limitations of our analysis require discussion. Despite the large number of participants, power for subgroup analyses was limited by the available data; most trials measured only 1 or 2 vascular outcomes, and some baseline variables were not collected in all trials. Caution is warranted in overinterpreting the results of positive associations in the IPD subgroup analyses; the large number of comparisons poses a risk of type I statistical error. Conversely, our decision to combine results from active treatment arms in trials with more than 1 active treatment arm risks diluting the apparent size of any treatment effect, although the impact of this is likely to be minimal given the small number of trials with more than 1 active treatment arm. For some outcomes, heterogeneity of measurement techniques required use of SMDs. Use of SMD limits the clinical utility of the results, and the heterogeneity of measurements means that translating SMD results to clinically meaningful values is challenging. However, use of SMD does at least allow some inferences about possible effect direction and magnitude to be obtained. Despite an extensive series of hypothesis‐driven subgroup analyses and metaregressions to examine potential causes for heterogeneity, we were unable to identify subgroups of patients more likely to benefit from intervention, and heterogeneity in our IPD subgroup analyses remained high. Some of this heterogeneity may be attributable to the small number of trials in each analysis, but other, unmeasured sources of real difference between trials may still exist.

Although the risk of bias in most trials was low, only half of the included trials analyzed data by intention to treat, and the inclusion of trials with non‐intention‐to‐treat analyses will tend to inflate observed effect sizes. It is also possible that not all eligible trials were found or included; for some trials, published trial reports had not been produced or could not be obtained from the authors. New trials continue to be published in this area, but most continue to use small numbers of participants and are likely to have limited impact on our conclusions. Not all authors were willing to share their IPD, and not all trial reports contained sufficient information to allow data to be extracted for meta‐analysis. A further limitation is inherent in the populations studied; most populations contained only a minority of participants with 25(OH)D levels below 25 nmol/L, a group that would be thought to be most likely to benefit. Similarly, some trials were conducted in groups without overt vascular disease, where again the possibilities for improving vascular function might have been limited. Most trials were conducted in white populations, which potentially limits the generalizability of the findings. In particular, few blacks were enrolled in the included studies; this group have particularly low 25(OH)D levels when living at high latitudes and may be more likely to show a reduction in BP with vitamin D supplementation.[53](#jah33189-bib-0053){ref-type="ref"}

A range of vitamin D doses were used in the included trials; debate continues as to what dose of vitamin D is optimum or indeed what the target level of 25(OH)D should be. If a level of 75 nmol/L is regarded as optimum as has been suggested from observational studies,[54](#jah33189-bib-0054){ref-type="ref"} doses at the upper end of the range included in this analysis are required to reach this level.[40](#jah33189-bib-0040){ref-type="ref"}, [55](#jah33189-bib-0055){ref-type="ref"}, [56](#jah33189-bib-0056){ref-type="ref"} Metaregression of vitamin D dose versus treatment effect suggested that higher doses of vitamin D were associated with a slightly greater treatment effect for FMD, but not for PWV or AIx. We found no evidence that daily dosing was more efficacious than intermittent dosing, despite previous work that has suggested that daily dosing provides more‐consistent tissue exposure to the parent compound, facilitating uptake and autocrine activation,[57](#jah33189-bib-0057){ref-type="ref"} and evidence that daily dosing may be more efficacious in some conditions (eg, respiratory disease).[58](#jah33189-bib-0058){ref-type="ref"} Our results are consistent with our previous analysis that did not find a difference between daily and intermittent dosing on BP.[5](#jah33189-bib-0005){ref-type="ref"} A final explanation that requires consideration is that the duration of therapy in most trials may simply have been too short to produce biological effects---particularly those trials intervening for only a few weeks. This explanation is plausible for outcomes such as arterial stiffness if biological effects are mediated by changes in vascular calcification, but seems less so for outcomes such as FMD and reactive hyperemia index, where other interventions are known to alter these parameters within days or weeks. Further evidence against this hypothesis is provided by the metaregression results, which suggest that longer trial duration was associated with a smaller treatment effect for FMD.

The results of these analyses add to the growing body of evidence suggesting that vitamin D supplementation may not have any beneficial effects on cardiovascular health. The lack of effect on vitamin D supplementation on BP in most studies to date[5](#jah33189-bib-0005){ref-type="ref"}, [53](#jah33189-bib-0053){ref-type="ref"} and the lack of effect on vascular markers observed in the current analysis suggests that associations between 25(OH)D levels and cardiovascular events observed in observational studies may not be causal. Not all observational studies have been prospective in nature, and the degree of adjustment for confounders has been variable. There are several reasons why assumptions about causality may be incorrect, including reverse causality (where overt or preclinical illness leads to lower 25(OH)D levels through mechanisms such as immobility, obesity, or inflammation[59](#jah33189-bib-0059){ref-type="ref"}, [60](#jah33189-bib-0060){ref-type="ref"}), and confounding by shared risk factors for both cardiovascular disease and low 25(OH)D levels; obesity, inactivity, smoking, and advanced age are all known to be associated with lower 25(OH)D levels, and such confounding is notoriously difficult to fully adjust for. Existing evidence from meta‐analyses of vascular events in osteoporosis trials using vitamin D does not support an effect of vitamin D in lowering cardiovascular event rates,[1](#jah33189-bib-0001){ref-type="ref"}, [7](#jah33189-bib-0007){ref-type="ref"} with the possible exception of heart failure, and the first of a new wave of large, population‐based vitamin D trials has recently reported, again showing no effect of vitamin D supplementation on cardiovascular event rates.[8](#jah33189-bib-0008){ref-type="ref"} Randomized trials of relatively short duration cannot exclude a benefit of vitamin D supplementation over the span of a lifetime; observational designs including Mendelian randomization studies[61](#jah33189-bib-0061){ref-type="ref"} may still be the only way to shed light on very long exposures to vitamin D, although even these designs are subject to bias and confounding.

A number of other large vitamin D trials are due to report over the next 3 to 4 years,[62](#jah33189-bib-0062){ref-type="ref"} and most of these include cardiovascular events as key outcomes---outcomes which our analysis did not focus on. Existing evidence does not support the use of vitamin D to reduce cardiovascular risk, and the results of our analysis do not suggest a specific target group that is particularly likely to benefit from vitamin D supplementation, although we found no evidence of a deleterious effect on cardiovascular function. The relative lack of representation of some groups, particularly nonwhite groups, tempers the generalizability of this conclusion. In the absence of a subgroup with clear benefit, and with large trial reports expected soon, further small‐scale trials examining surrogate vascular end points are unlikely to advance this field of research significantly.
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